|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Save the Date! 91st Annual Meeting - Oct. 25-29, 2015
Indian Wells, CA.
Top Healthcare Quality Issues for 2015, Part 2
Results of a "trifecta" of databases on provider quality and cost that will be released in 2015 are among the leading quality issues for the year. The previous list discussed misdiagnoses, star ratings, socioeconomic adjustment for readmissions, the end of Partnership for Patients programs, Medicaid parity expiration, and Disproportionate Share Hospital cuts. Today, seven more pressuring healthcare quality issues for 2015.
| Share this article:
Looking for similar articles? Search here, keyword Urology.
Addressing Prostate Cancer Patient Concerns
HealthDay News via Renal & Urology News
Many cancer survivors in the U.S. have unresolved physical and mental health issues long after being cured, according to a study published online Jan. 12 in Cancer.
The new study involved 1,514 cancer survivors who completed an American Cancer Society survey asking about unmet needs. More than one-third (38.2 percent) pointed to physical problems related to their cancer or its treatment. For example, incontinence and sexual problems were especially common among prostate cancer survivors, the researchers found.
Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review
Agency for Healthcare Research and Quality
Prostate cancer is the most common nondermatologic cancer in men. The American Cancer
Society has estimated that 241,740 men were expected to receive a diagnosis of prostate cancer
in 2012, and 28,170 were expected to die from the disease.
Approximately 90 percent of those
who receive such a diagnosis have cancer confined to the prostate gland, which is the definition
of clinically localized disease. Since 2004, the prostate cancer incidence rate has decreased by
2.7 percent annually among men 65 years of age or older and has remained steady among men
younger than age 65. The major risk factors for prostate cancer are advanced age, race and
ethnicity (the highest incidence is in blacks), and family history.
We serve the molecular testing needs of Urologists and Pathologists, and other reference laboratories, with a specialized emphasis in proprietary testing for Prostate and Bladder Cancer patients.
Our area of particular focus is the early detection of genomic changes, through Fluorescence in situ Hybridization (FISH) technology, that may detect cancer, measure the potential aggressiveness of the disease, as well as identify patients most likely to respond to targeted therapies.
We offer flexible testing solutions that are tailored to each client's needs.
Allopurinol May Slow Kidney Disease Progression
Renal & Urology News
Long-term treatment with allopurinol may slow the rate of progression of kidney disease and decrease cardiovascular (CV) risks, according to a new study published online ahead of print in the American Journal of Kidney Diseases. The study, which was a post-hoc analysis of long-term follow-up of a 2-year randomized controlled trial of allopurinol, included 113 participants with an estimated glomerular filtration rate below 60 mL/min/1.73 m2. Of these, 57 received treatment with allopurinol and 56 continued on their standard treatment (controls).
Why Universal Health Services Jumped Across the Pond
In fall 2014, Universal Health Services, a for-profit operator of acute-care and behavioral-health facilities, acquired Cygnet Health Care for $335 million. Cygnet operates inpatient behavioral-health hospitals throughout the United Kingdom. UHS CEO Alan Miller said at the time that the transaction gave the King of Prussia, Pennsylvania-based company entry into a new market. But there's more to it.
Why Drugs Cost So Much
The New York Times
Eli Lilly charges more than $13,000 a month for Cyramza, the newest drug to treat stomach cancer. The latest medicine for lung cancer, Novartis's Zykadia, costs almost $14,000 a month. Amgen's Blincyto, for leukemia, will cost $64,000 a month.
Why? Drug manufacturers blame high prices on the complexity of biology, government regulations and shareholder expectations for high profit margins. In other words, they say, they are hamstrung. But there's a simpler explanation.
11 Healthcare Buzzwords for 2015
As the fifth anniversary of the passage of the Patient Protection and Affordable Care Act nears, providers are continuing to adjust to dramatic changes in the way they deliver care and administer their business practices,
The language used to describe these changes is also evolving. Some of it is borrowed from other industries, some of it is home-grown; all of it is in flux.
This glossary of jargon was culled from chatter overheard at healthcare conferences, interviews with industry leaders, and the pages of medical journals.
Researchers Propose New Regulations for Off-Label Uses of Drugs and Devices
Off-label use of drugs and medical devices has long been a part of medicine. The practice provides public health benefits but also presents some risks. To address that issue, researchers from the David Geffen School of Medicine at UCLA have proposed a system combining reporting, testing and enforcement regulations, and allowing interim periods of off-label drug prescription. Their recommendations, published in the Duke Law Journal, would give patients more treatment options while providing regulators with evidence of the drugs' safety and efficacy.
Too Close to a Patient for Comfort
The New York Times
How many degrees of separation are needed between patient and doctor for effective medical care? The correct answer is "many," or even "as many as possible," a dictum so counterintuitive that everyone routinely violates it. Surveys indicate that almost all doctors have been asked to provide some form of informal medical care to a close relative, and almost all of them have obliged, even though most hospitals and many professional organizations warn against it. Doctors often write prescriptions, sometimes supervise a hospital stay and occasionally perform surgery or provide continuing primary care.
California Rejects UnitedHealth's Bid to Sell Obamacare Statewide
The Los Angeles Times
California's Obamacare exchange rejected a bid from the nation's largest health insurer to start selling coverage statewide in 2016. The Covered California board adopted new rules Thursday, Jan. 15, that sharply limit where industry giant UnitedHealth Group Inc. could offer policies to individuals.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063